Venmax Drugs And Pharmaceuticals Share Price
14.85+0.04 (+9.19%)
-43.75% past 1 Year
Corporate filings & documents
Announcements
Venmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limited (Amalgamating Company) with Venmax Drugs and Pharmaceuticals Limited ( Amalgamated Company).
1 week agoVenmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limited (Amalgamating Company) with Venmax Drugs and Pharmaceuticals Limited ( Amalgamated Company).
1 week agoSubmission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements) 2015.
2 weeks agoSubmission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements) 2015.
2 weeks agoPursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 we would like to inform you that a meeting of Board of Directors of was held today i.e August 31 2026 at the registered office of the Company.
2 weeks agoPursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 we would like to inform you that a meeting of Board of Directors of was held today i.e August 31 2026 at the registered office of the Company.
2 weeks agoVenmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 inter alia to consider and approve matters related to Annual General Meeting and any other business as the board deems fit to discuss with the permission of the chairman.
3 weeks agoVenmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 inter alia to consider and approve matters related to Annual General Meeting and any other business as the board deems fit to discuss with the permission of the chairman.
3 weeks agoNewspaper Publication of the Unaudited Financial Results for the Quarter ended June 30 2026.
1 month agoNewspaper Publication of the Unaudited Financial Results for the Quarter ended June 30 2026.
1 month agoStatement of Deviation & Variation for the Quarter ended June 30 2026.
1 month agoStatement of Deviation & Variation for the Quarter ended June 30 2026.
1 month agoUnaudited Financial Results along with Limited Review Report for the Quarter ended June 30 2026.
1 month agoUnaudited Financial Results along with Limited Review Report for the Quarter ended June 30 2026.
1 month agoUnaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30 2026.
1 month agoUnaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30 2026.
1 month agoVenmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Unaudited financial results for the quarter ended June 30 2026.
1 month agoVenmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Unaudited financial results for the quarter ended June 30 2026.
1 month agoAllotment of 7 53 334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation 2015.
1 month agoAllotment of 7 53 334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation 2015.
1 month agoAllotment of 21 47 665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulation 2015.
1 month agoAllotment of 21 47 665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulation 2015.
1 month agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
2 months agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
2 months agoIntimation of Closure of Trading Window pursuant to declaration of unaudited financial results for the quarter ended June 30 2026.
2 months agoIntimation of Closure of Trading Window pursuant to declaration of unaudited financial results for the quarter ended June 30 2026.
2 months agoStatement of Deviation & variation for the Quarter and Year ended March 31 2026.
4 months agoStatement of Deviation & variation for the Quarter and Year ended March 31 2026.
4 months agoNewspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31 2026.
4 months agoNewspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31 2026.
4 months agoAudited Financial Results for the Quarter and Year ended March 31 2026
4 months agoAudited Financial Results for the Quarter and Year ended March 31 2026
4 months agoVenmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31 2026.
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Venmax Drugs and Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1988PLC009102</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Agarwal <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Kummarikuntla Saibaba <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months agoSubmission of Annual Secretarial Compliance Report for the year ended March 31 2026.
5 months agoSubmission of Annual Secretarial Compliance Report for the year ended March 31 2026.
5 months agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.
5 months agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.
5 months agoDisclosure under Regulation 31 (4) of SEBI (SAST) Regulations 2011
5 months agoThe Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director Non Executive and Non Independent Director and Mr. Revoor Ramachandra as an Additional director Non Executive Independent Director of the Company.
5 months agoThe Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director Non Executive and Non Independent Director and Mr. Revoor Ramachandra as an Additional director Non Executive Independent Director of the Company.
5 months agoApproval of Modification of draft Scheme of Amalgamation submitted on November 12 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited (Transferee Company)
5 months agoApproval of Modification of draft Scheme of Amalgamation submitted on November 12 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited (Transferee Company)
5 months agoIntimation of Closure of Trading Window pursuant to declaration of Audited Financial Results for the Quarter and Year ended March 31 2026.
5 months agoIntimation of Closure of Trading Window pursuant to declaration of Audited Financial Results for the Quarter and Year ended March 31 2026.
5 months agoAllotment of 28 00 000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations 2015
6 months agoAllotment of 28 00 000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations 2015
6 months agoChange in designation of Mr. Venkata Rao Sadhanala whole Time director as Managing Director of the company for a period of 5 years w.e.f. March 11 2026 subject to approval of shareholders.
6 months agoChange in designation of Mr. Venkata Rao Sadhanala whole Time director as Managing Director of the company for a period of 5 years w.e.f. March 11 2026 subject to approval of shareholders.
6 months agoNewspaper Publication of unaudited financial results for the quarter and nine months ended December 31 2025.
7 months agoAnnual reports
Concalls & investor presentations
No presentations found